Cologuard
Commercial- Indications
- Colorectal cancer screening
Company intelligence / Profile preview
Dune Medical Devices developed the MarginProbe System, an FDA-approved intraoperative device that uses radiofrequency spectroscopy to detect cancer at the margins of excised breast tissue during lumpectomy. Clinical studies have shown up to a 79% reduction in re-excision rates for women undergoing breast-conserving surgery. The company also developed a Smart Biopsy device leveraging its RF technology for real-time soft tissue characterization, with support from EU Horizon 2020 grants. In April 2020, Dune was acquired by Dilon Technologies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dune Medical Devices.